Rise Advisors LLC Invests $28,000 in Exelixis, Inc. (NASDAQ:EXEL)

Rise Advisors LLC bought a new position in Exelixis, Inc. (NASDAQ:EXEL) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 1,189 shares of the biotechnology company’s stock, valued at approximately $28,000.

Several other institutional investors have also recently made changes to their positions in EXEL. Fisher Asset Management LLC increased its position in Exelixis by 232.6% during the 4th quarter. Fisher Asset Management LLC now owns 1,041 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 728 shares in the last quarter. Contravisory Investment Management Inc. purchased a new stake in Exelixis during the 4th quarter valued at $26,000. GAMMA Investing LLC purchased a new stake in Exelixis during the 4th quarter valued at $27,000. USA Financial Formulas boosted its stake in Exelixis by 1,548.0% during the 4th quarter. USA Financial Formulas now owns 2,060 shares of the biotechnology company’s stock valued at $49,000 after purchasing an additional 1,935 shares during the last quarter. Finally, KBC Group NV purchased a new stake in Exelixis during the 4th quarter valued at $145,000. Institutional investors own 85.27% of the company’s stock.

Insiders Place Their Bets

In other Exelixis news, Director Jack L. Wyszomierski sold 8,287 shares of the business’s stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $22.00, for a total transaction of $182,314.00. Following the sale, the director now directly owns 349,499 shares of the company’s stock, valued at $7,688,978. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Exelixis news, Director George Poste sold 11,686 shares of the business’s stock in a transaction that occurred on Tuesday, May 21st. The stock was sold at an average price of $20.96, for a total transaction of $244,938.56. Following the sale, the director now directly owns 213,907 shares of the company’s stock, valued at $4,483,490.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jack L. Wyszomierski sold 8,287 shares of the business’s stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $22.00, for a total value of $182,314.00. Following the transaction, the director now owns 349,499 shares of the company’s stock, valued at approximately $7,688,978. The disclosure for this sale can be found here. Insiders have sold 30,896 shares of company stock valued at $660,677 over the last ninety days. 2.85% of the stock is owned by insiders.

Analysts Set New Price Targets

Several analysts have commented on the company. William Blair reiterated an “outperform” rating on shares of Exelixis in a research note on Wednesday, May 1st. StockNews.com downgraded Exelixis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, June 4th. TheStreet upgraded Exelixis from a “c+” rating to a “b-” rating in a research note on Monday, March 18th. JMP Securities restated a “market outperform” rating and issued a $27.00 price target on shares of Exelixis in a research note on Wednesday, April 10th. Finally, Barclays downgraded Exelixis from an “overweight” rating to an “equal weight” rating and set a $25.00 target price on the stock. in a research report on Thursday, April 11th. Seven equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $26.13.

Exelixis Trading Up 0.8 %

Shares of EXEL stock opened at $21.73 on Friday. Exelixis, Inc. has a 12-month low of $18.64 and a 12-month high of $24.34. The stock’s 50-day moving average price is $21.92 and its 200-day moving average price is $22.34. The stock has a market capitalization of $6.59 billion, a price-to-earnings ratio of 33.95, a price-to-earnings-growth ratio of 0.53 and a beta of 0.56.

Exelixis (NASDAQ:EXEL) last issued its earnings results on Tuesday, April 30th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.28 by ($0.16). Exelixis had a return on equity of 8.85% and a net margin of 11.10%. The firm had revenue of $425.23 million during the quarter, compared to the consensus estimate of $461.04 million. During the same period last year, the firm posted $0.12 earnings per share. The company’s revenue for the quarter was up 4.0% compared to the same quarter last year. As a group, research analysts predict that Exelixis, Inc. will post 1.15 EPS for the current fiscal year.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.